- Home
- SWZ vs ACRV Comparison
SWZ vs ACRV Comparison
Compare SWZ & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SWZ | ACRV |
|---|---|---|
| Founded | 1986 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.3M | 68.5M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | SWZ | ACRV |
|---|---|---|
| Price | $5.88 | $1.57 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | 37.5K | ★ 456.9K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 6.59% | N/A |
| EPS Growth | N/A | ★ 15.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $568.17 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.84 | $1.20 |
| 52 Week High | $6.43 | $3.56 |
Technical Indicators
Market Signals| Indicator | SWZ | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 41.65 | N/A |
| Support Level | $5.86 | N/A |
| Resistance Level | $6.10 | N/A |
| Average True Range (ATR) | 0.04 | 0.00 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 20.22 | 0.00 |
Price Performance
Historical ComparisonAbout SWZ Swiss Helvetia Fund Inc. (The)
Swiss Helvetia Fund Inc is a non-diversified, closed-end investment company. Its investment objective is to seek long-term capital appreciation through investment in equity and equity-linked securities of Swiss companies. It actively manages investment solutions spanning public and private markets, wealth management, and Solutions.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.